Value
3.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 6.0 |
ALMR · Why this verdict
Why Alamar Biosciences (ALMR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Alamar Biosciences is growing revenue 99% YoY as an industry leader, but the stock has already reached its prior analyst target with a failed asymmetry gate, a momentum score sitting exactly at the pass-fail line, and an expensive, leverage-penalized valuation, leaving little room for further re-rating.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is growing 99% YoY, and the peer-ranking model flags the company as an industry growth leader. Growth breakdown | Revenue growth should stay well above the sector average for the growth-leader thesis to hold over the next 12 months. | →Stable |
| CounterTriple-digit growth off a small base is common in early-stage medical device companies and often decelerates sharply as the base grows. | ||
The stock has already reached its prior analyst price target, leaving only about 0.6% modeled upside from current levels. Warnings | Modeled upside should expand meaningfully if analysts issue higher targets following continued growth. | Tripped→Stable |
| CounterA 99% revenue growth rate could justify analysts raising targets soon, which would quickly restore modeled upside. | ||
The asymmetry ratio sits at just 0.04, failing the 1.5 minimum bar, while momentum sits exactly at its own 4.5 pass-fail threshold, a fragile setup on both fronts. Engine gate (failed) | Asymmetry should climb meaningfully above 1.5 and momentum should clear 4.5 with room to spare for the setup to strengthen. | →Stable |
| CounterA momentum score sitting exactly at the threshold could just as easily resolve upward given the underlying growth strength. | ||
The stock carries an expensive valuation alongside a leverage penalty applied by the scoring engine given a D/E of 1.9. Bear case | Debt-to-equity should decline from the current 1.9 for the leverage penalty to ease. | →Stable |
| CounterA growth-stage medical device company may use leverage strategically to fund expansion without it signaling financial distress. | ||
Revenue is growing 99% YoY, and the peer-ranking model flags the company as an industry growth leader.
→StableGrowth breakdown
- Expectation
- Revenue growth should stay well above the sector average for the growth-leader thesis to hold over the next 12 months.
CounterTriple-digit growth off a small base is common in early-stage medical device companies and often decelerates sharply as the base grows.
The stock has already reached its prior analyst price target, leaving only about 0.6% modeled upside from current levels.
Tripped→StableWarnings
- Expectation
- Modeled upside should expand meaningfully if analysts issue higher targets following continued growth.
CounterA 99% revenue growth rate could justify analysts raising targets soon, which would quickly restore modeled upside.
The asymmetry ratio sits at just 0.04, failing the 1.5 minimum bar, while momentum sits exactly at its own 4.5 pass-fail threshold, a fragile setup on both fronts.
→StableEngine gate (failed)
- Expectation
- Asymmetry should climb meaningfully above 1.5 and momentum should clear 4.5 with room to spare for the setup to strengthen.
CounterA momentum score sitting exactly at the threshold could just as easily resolve upward given the underlying growth strength.
The stock carries an expensive valuation alongside a leverage penalty applied by the scoring engine given a D/E of 1.9.
→StableBear case
- Expectation
- Debt-to-equity should decline from the current 1.9 for the leverage penalty to ease.
CounterA growth-stage medical device company may use leverage strategically to fund expansion without it signaling financial distress.
Per-dimension breakdown
Quality
4.4/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 7.4 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.1 |
| Moat | 6.5 |
| Piotroski F | 5.6 |
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 99% YoY
Momentum
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 0.0 |
| OBV | 6.6 |
| MA position | 4.5 |
| Volume | 0.0 |
Sentiment
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.5 |
| Price target | 8.3 |
| erm sentiment | 5.8 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 27%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.0 |
| quality rank | 1.2 |
| growth rank | 9.5 |
- ▸Industry growth leader
Technical
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.9 |
| support resistance | 6.4 |
| 52w position | 7.1 |
Risk (lower is worse)
3.1/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 6.7 |
| days to cover | 2.5 |
| volatility | 0.0 |
| debt equity | 3.3 |
Catalyst
5.0/10data confidence 25%| Component | Sub-score |
|---|---|
| erm | 5.0 |
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.1<4.5
- ASYMMETRY:0.7<1.5@spot
Warning (0)
none
Reward-to-Risk
0.68
Upside
+10.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 46 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $1.7B<$5B
Investment implication
The F-path SELL output reflects an overall score of 4.5 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:3.1<4.5, ASYMMETRY:0.7<1.5@spot) reinforce the read. Current asymmetry R:R is 0.68 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Insider at 7.3, and Sentiment at 6.9; the weakest are Peer rank at 2.9, Risk (lower is worse) at 3.1, and Momentum at 3.1. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 0.68 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Revenue Growth Industry Leader
Trip ifRevenue growth falls below 40% YoY from the current 99%.
- P2Target Already ReachedTripped
Trip ifModeled upside to price target rises above 15% from the current 0.6%.
- P3Failed Asymmetry At Momentum Floor
Trip ifAsymmetry ratio rises above 1.5 from the current 0.04.
- P4Expensive Valuation Leverage Penalty
Trip ifDebt-to-equity ratio falls below 1.0 from the current 1.9.